血管紧张素II及其受体与恶性肿瘤关系的研究进展

摘要

Angiotensin AngII, a linear small peptide,which is composed of eight amino acids, is the main effectors of renin-angiotensin systen (Renin-angiotensin system, ARS). AngII, a main biopolypeptide of the ARS, has important patho-physiologic in effects participating in cardiac hypertrophy, vascular cell proproliferation, inlfammation and tissue remodeling through G-protein-coupled receptors. In recent years, Ang II can promote tumor cell proliferation, tumor vessel formation and inhibit the differentiation of the tumor cells. hTis suggests that inhibit the production of AngII or block its effect is expected to become a new measure for the treatment of malignant tumors. hTis article reviews the advances in research on the relationship between AngII and its receptor and malignant tumor in recent years.%血管紧张素II（angiotensin II, AngII）是由8个氨基酸组成的线性小肽，是肾素-血管紧张素系统（re-nin-angiotensinsystem, ARS）主要的效应因子。AngII主要的作用受体有两个，血管紧张素II1型（angiotensin II 1 recep-tor, AT1R）和AT2R分别是AngII作用于靶细胞表面的特异性G蛋白偶联1型和2型受体。AngII通过上述两种受体参与调节血管舒缩、水盐平衡、炎性反应、细胞增殖、细胞凋亡等生物学功能。近年来发现AngII具有促进肿瘤细胞增殖、肿瘤血管形成并抑制肿瘤细胞分化的功能。这提示抑制AngII的产生或阻断其作用有望成为治疗恶性肿瘤的一项新措施。本文就近年来关于AngII及其受体与恶性肿瘤关系的研究进展作一综述。